Fundz
New|Fundz now works inside Claude2 min

Timing. Relevance. Relationships.

Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.

Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015
Back to SEC Filings
Executive ChangeItem 5.02 · 8-KMEDIUM RiskNegative

Jasper Therapeutics, Inc.

A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.

www.jaspertherapeutics.com
Filed: Sep 23, 2026Redwood City, CaliforniaCIK: 0001788028Health Care
Full company profileView on SEC.gov

The seat is still open. No replacement has been named 16 days after this filing.

See every company with multiple executive changes →

AI Executive Summary

AI-powered analysis of 8-K filing content

Jasper Therapeutics' CFO Herb Cross resigned effective October 9, 2026, prompting the board to appoint interim replacements across financial and corporate governance roles. This leadership transition creates near-term uncertainty around financial oversight and strategic direction during a critical period for the biotech company.

Key Takeaways

Herb Cross resigned from CFO, Principal Financial Officer, Principal Accounting Officer, and Corporate Secretary roles due to other professional pursuits

Jeet Mahal (President and CEO) assumed interim Principal Financial Officer duties, creating dual responsibilities at the executive level

2 more takeaways

Filing Overview

Form Type8-K
Filing DateSep 23, 2026
Item5.02
CategoryExecutive Change
CIK0001788028
Accession #0001213900-26-104101
Risk LevelMEDIUM
SentimentNegative
Signalrisk
Topics
executive departureleadership transition

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings

Jasper Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

4 screens from a live account. No signup.